ExploRNA Therapeutics is a spin-off from the University of Warsaw, developing next generation mRNA technology for applications such as anti-cancer vaccines. ExploRNA Therapeutics was founded by Professor Jacek Jemielity, Head of the Bio Organic Chemistry Laboratory at the Center of New Technologies CeNT at the University of Warsaw. Professor Jemielity’s first generation ‘cap modification’ mRNA […]

View post to subscribe to site newsletter.

Acrigen Biosciences is developing technologies to improve the efficiency and enhance the safety of CRISPR-Cas based gene editing, with the aim of eliminating the threat of unintended editing causing severe complications and side effects. The company’s technology is based on a class of proteins, anti-CRISPR or Acr proteins, that precisely deactivate the Cas proteins serving […]

View post to subscribe to site newsletter.

New Equilibrium Biosciences has developed a computational–experimental platform to discover lead drug candidates that regulate intrinsically disordered proteins implicated in cancers and neurodegenerative disorders. The company says that about 30% of proteins are predicted to not have a single 3D structure. Instead, they have evolved to fluctuate between an ensemble of short-lived conformations, which enable […]

View post to subscribe to site newsletter.